The generic version of popular diabetes drug Empagliflogen has reached the market after the end of the patient of Bohringer England on 11 March. The German pharmaceutical company sold it under the brand name Jardius.

Mankind Pharma, India’s fourth largest firm from market share, is selling a general version of the drug in the tenth part of the cost. According to the company, the cost of Empagliflogen, which was earlier priced at Rs 60 per tablet, will now cost Rs 6 per tablet.

Rajiv Junja, Vice Chairman and Managing Director, Manikind Pharma said, “By introducing Empagliflogen at Rs 5.49 per tablet for 10 mg variants and Rs 9.90 per tablet for 25 mg variants, we are sure that the cost is no longer an obstacle to access the cost.”

“With this launch, Mankind Pharma has once again broken the cost barriers by offering a product that combines international quality with strength,” Juneja said.

Empagliflozin is a SGLT-2 (sodium-glucose cum-transporter-2) used with diet and exercise for the treatment of type 2 diabetes or diabetes mellitus, chronic kidney disease and chronic heart failure.

The drug works by blocking SGLT-2 protein in the kidney, which is responsible for withdrawing glucose (sugar) back into the bloodstream. It helps the kidneys to emit more glucose in the urine, thus reduces blood sugar levels.

Empagliflozin is part of a square of drugs, known as SGLT2 inhibitors, including cannagliflogen and dapagliflozin. These drugs are usually used with diet and exercise to manage type 2 diabetes.

Mankind Pharma has launched Empagliflogen under brand names: Empagleed, Empagrate and Dianaduo.

Empaglyde tablets start from Rs 54.90, available in 10 mg to 25 mg, with variants – M, L, and S. Empagrate tablets also include, which start from Rs 54.90, available in 10 mg to 25 mg, including variants – M and S. Dianaduo tablets start at Rs 79.90.

Other domestic firms launching the generic brands of the drug include Alkem Laborators, Torrent and Lupine. “With a patient-centered approach, Alkem has introduced an anti-counterfit security band on the pack of imperialism, as well as comprehensive patient education information, including the basic details on diabetes management in Hindi and English with infographics, and QR codes, which provide information on diabetes, heart failure, and chronic kidney disease.

ALKEM has launched the drug under the cost of about 80% less brand than the cost of innovator products.

Glenmark Pharmaceuticals Limited has also introduced a common drug of Empaglogen under the brand name Glampa (Empagliflogen 10/25 mg), as well as its fixed-dose combinations (FDCS) Glamp-L (Empagloflose 10/25 ml + linagliptin 5 mG) and Glampin 5 MGAG) 500/1000 mg).

These drugs are designed to improve glycemic control in adults with type 2 diabetes, while cardiovascular risk type 2 diabetic patients are also reduced to cardiovascular results.

GLEMPA (Empagliflozin 10mg/25mg) serves as a standalone SGLT2 inhibitor to improve glycemic control by reducing heart risks. GLEMPA-L (Empagliflozin 10/25 Mg + Linagliptin 5 Mg) is a dual-action therapy by combining a SGLT2 inhibitor with DPP4 inhibitors for more effective management of T2DM with cardio renal risks.

Meanwhile, Glempa M (Empagliflozin 12.5 Mg + Metformin 500/1000 Mg) combines the benefits of SGLT2 prohibition with proven efficacy of Metformin, making it an optimal option for patients requiring strong glycemic control.

The launch of the Glampa range confirms this commitment by providing a broad and inexpensive solution that gives health professionals and patients the right to manage Type 2 diabetes to establish type 2 diabetes more effectively, “said the chairman of India and the head of Glenmark Pharmaceutical Limited.

Glempa 10mg per tablet costs at Rs 11, while the price of 25 mg is Rs 14.

Along with over 100 million people diagnosing diabetes in India, low -cost drugs can help combat this increasing burden in the country as most patients remove treatment costs due to limited medical reimbursement options.